JP2014074667A - α−ガラクトシダーゼ濃度を測定する方法 - Google Patents
α−ガラクトシダーゼ濃度を測定する方法 Download PDFInfo
- Publication number
- JP2014074667A JP2014074667A JP2012222578A JP2012222578A JP2014074667A JP 2014074667 A JP2014074667 A JP 2014074667A JP 2012222578 A JP2012222578 A JP 2012222578A JP 2012222578 A JP2012222578 A JP 2012222578A JP 2014074667 A JP2014074667 A JP 2014074667A
- Authority
- JP
- Japan
- Prior art keywords
- galactosidase
- antibody
- fabry disease
- protein
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010030291 alpha-Galactosidase Proteins 0.000 title claims abstract description 62
- 102000005840 alpha-Galactosidase Human genes 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 36
- 210000002381 plasma Anatomy 0.000 claims abstract description 29
- 210000002966 serum Anatomy 0.000 claims abstract description 26
- 210000004369 blood Anatomy 0.000 claims abstract description 18
- 239000008280 blood Substances 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims abstract description 15
- 210000001519 tissue Anatomy 0.000 claims abstract description 13
- 208000024720 Fabry Disease Diseases 0.000 claims description 68
- 230000000694 effects Effects 0.000 claims description 12
- 102000017852 Saposin Human genes 0.000 claims description 3
- 108050007079 Saposin Proteins 0.000 claims description 3
- 238000005259 measurement Methods 0.000 abstract description 4
- 150000007523 nucleic acids Chemical group 0.000 description 46
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 30
- 230000027455 binding Effects 0.000 description 25
- 238000001514 detection method Methods 0.000 description 18
- 101710120037 Toxin CcdB Proteins 0.000 description 17
- 239000011324 bead Substances 0.000 description 17
- 235000020958 biotin Nutrition 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 229960002685 biotin Drugs 0.000 description 15
- 239000011616 biotin Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090001008 Avidin Proteins 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108010090804 Streptavidin Proteins 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000004132 cross linking Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000003431 cross linking reagent Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000010382 chemical cross-linking Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- -1 linker compound Chemical class 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 108010056760 agalsidase beta Proteins 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LRPQMNYCTSPGCX-UHFFFAOYSA-N dimethyl pimelimidate Chemical compound COC(=N)CCCCCC(=N)OC LRPQMNYCTSPGCX-UHFFFAOYSA-N 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 108010087904 neutravidin Proteins 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 101710132570 Protein G1 Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 229960004470 agalsidase beta Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 108700021042 biotin binding protein Proteins 0.000 description 1
- 102000043871 biotin binding protein Human genes 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 1
- 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940014516 fabrazyme Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/10—Oligonucleotides as tagging agents for labelling antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7057—(Intracellular) signaling and trafficking pathways
- G01N2800/7066—Metabolic pathways
- G01N2800/7085—Lipogenesis or lipolysis, e.g. fatty acid metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
【解決手段】血液、血清、血漿中、または細胞や組織中において、MUSTag法を用いて、α−ガラクトシダーゼ濃度を測定する。
【選択図】なし
Description
MUSTag化抗体は、例えば、国際公開公報WO2010/001891に記載されている。本文献を引用して、本明細書に援用する。
核酸鎖、抗α−ガラクトシダーゼ抗体、及び核酸鎖と抗体を結合するアダプター部位を含有するMUSTag化抗体の作製方法は、これらの構成要素を含有するように製造できれば、特に限定されないが、例えば、国際公開公報WO2010/001891に記載された方法を用いることができる。
抗原としてのα−ガラクトシダーゼの検出に用いるサンプルは、血液であっても、血清であっても、血漿であってもよい。例えば、診断対象のヒトから末梢血を採血し、公知の方法で処理することにより、サンプルを調製することができる。
まず、診断対象の患者から、検査対象のサンプルを採取する。侵襲性の低さのため、末梢血を採血するのが好ましい。その後、得られた血液から、血清または血漿を調製してもよい。あるいは、患者の細胞や組織であってもよい。細胞や組織は特に限定されないが、白血球が好ましい。
MUSTag化抗体を用いたα−ガラクトシダーゼの検出を容易にするために、必要な試薬をFabry病の診断キットとしてキット化してもよい。
このキットは、標識としての核酸鎖α−ガラクトシダーゼに特異的に結合する抗体、及び核酸鎖と抗体を結合するアダプター部位を含有する抗体複合体を含有する。ここで、アダプター部位は、プロテインG、プロテインAまたはプロテインLのいずれかのイムノグロブリン結合ドメインを含有し、アダプター部位と抗体とは、化学的に架橋されていてもよい。
その他の抗体複合体の態様は、上述した通りである。
このキットには、架橋型抗体複合体の他に、他の構成成分を備えてもよく、様々なバッファー、プライマーや酵素などの検出用試薬を含んでいてもよい。
(1)MUSTag化抗α−ガラクトシダーゼ抗体の作製
(1−1)プロテインG/ストレプトアビジン/His-tag融合タンパク質の作製
まず、プロテインG/ストレプトアビジン/His-tagの融合タンパク質(以下、融合タンパク質と呼ぶ。)を作製した。
5'- CATATGCACTTACAAATTAATCCTTAA -3' (配列番号9)
プロテインGプライマーR:
5'- GAATTCGGATCCTTCACCGTCAACACCGTTG -3' (配列番号10)
ストレプトアビジンプライマーF:
5'- GAATTCAAGCTTGCCGGCATCACCGGCACCTG -3' (配列番号11)
ストレプトアビジンプライマーR:
5'- CTGCAGCTGCTGAACGGCGTCGAGCG -3' (配列番号12)
得られたDNA断片をEcoRIで切断後、ライゲーションによって結合させ、再度、プロテインGプライマーFとストレプトアビジンプライマーRを用いて、PCRを行い、融合DNA断片を増幅した。
配列番号15の配列(131塩基)を有するDNAをインサートしたpcDNA3 (Invitrogen社製)を鋳型DNAとし、ビオチン化プライマー(5-MUSTagBio)を含む下記プライマー(配列番号16及び17)を使用して〈95℃60秒−55℃60秒−72℃30秒を35サイクル〉の反応条件でPCRを行うことにより、5'末端がビオチン化されたオリゴヌクレオチド鎖#1(配列番号15)を合成した。
5’-[Biotin]-CACTGCTTACTGGCTTATCGAAATGGAATTCTGCATGCATCTAGAGGGCCCTATTCTATAGCATAGTGTCACCTAAATGCTAGGCACCTTCTAGTTGCCAGCCATCTGTTGCACACCAAACGTGGCTTGCC-3’ (配列番号15)
同様に、配列番号18の配列を有するDNAをインサートしたpcDNA3 (Invitrogen社製)を鋳型とし、同じプライマー(配列番号16、17)を用いて、5'末端がビオチン化されたオリゴヌクレオチド鎖#7(配列番号18)を合成した。
5’-[Biotin]-CACTGCTTACTGGCTTATCGAAATGGAATTCTGCATGCATCTAGAGGGCCCTATTCTATAGCATAGTGTCACCTAAATGCTAGGCAACCGACAATTGCATGAAGAACTCGCACATTGACGTCAATAATGACGTATGTTCCCACCACCAAACGTGGCTTGCC-3’ (配列番号18)
〈PCR用プライマーの配列〉
5-MUSTag primer Bio-F:
5'-[Biotin]-CACTGCTTACTGGCTTATCGAAA-3' (配列番号16)
3-MUSTag primer R:
5'-GGCAAGCCACGTTTGGTG-3' (配列番号17)
(1−3)MUSTag化抗α−ガラクトシダーゼ抗体の作製
微量遠心チューブに、結合バッファー(0.2 M Borate pH 9.0, 0.5 M NaCl, 0.1 mM EDTA, 0.05% Monocaprate)243.4 μl、融合タンパク質 6.6 μl(100 pmol)、ビオチン化オリゴヌクレオチド(配列番号15)を40 μl(100 pmol)加え、室温0.5時間、回転させながら、融合タンパク質のストレプトアビジン部位とビオチン化オリゴヌクレオチドを結合させた。その後、抗α−ガラクトシダーゼ抗体(0.5 mg/ml)を60 μl(200 pmol)加え、室温で1時間、回転させながら、融合タンパク質のプロテインG部位と抗体を結合させた。
機器:製品名:SMART system, 会社名:旧Pharmacia(現GE Healthcare, 製造中止品)
カラム:製品名:Superdex 200 PC 3.2/30, 会社名:GE Healthcare, 製品番号:17-1089-01)
バッファー:10 mM Tris-HCl pH 7.4, 0.5 M NaCl, 0.1 mM EDTA, 0.05% Monocaprate
流速:100 μl/min
(2)血漿サンプル中のα−ガラクトシダーゼ濃度の測定
(2−1)Fabry病患者血漿および血清サンプル中のα−ガラクトシダーゼの検出
磁気ビーズ(Dynabeads M-280 Tosylactivated, Invitrogen社)に捕捉用抗体(Anti-GLA mouse monoclonal antibody , clone No.:4F2G4, IgG1)をカップリング反応で結合させ、1%感作ビーズを作製した。1%感作ビーズは、測定まで4℃で保存した。なお、作製手順はDynabeads M-280 Tosylactivated, Invitrogen社のプロトコールに従って行った。
リアルタイムPCR法で得られたCt値よりGraphPad Prism version 5.02(GraphPad Software Inc.)を用いた非線形回帰分析を行い、血漿および血清中のα-ガラクトシダーゼ濃度を算出した。
リアルタイムPCR法で得られたスタンダードのヒトα-ガラクトシダーゼのCt値を用いて非線形回帰分析により検量線を算出し、図1に示した。3xSD法による検出限界を求めたところ、本測定時の検出限界は17.8 pg/mLであった。これらの検量線のR squareは0.9946であったので、この数式により求められる値は実際の値と近似した値を示すといえる。
Claims (4)
- 当該血液、血清、血漿中、または細胞や組織中において、α−ガラクトシダーゼ濃度を測定する方法であって、
MUSTag法を用いて、前記α−ガラクトシダーゼ濃度を測定する工程を含む方法。 - 請求項1に記載の方法であって、
前記測定したα−ガラクトシダーゼ濃度を用いて、当該血液、血清、血漿中、または細胞や組織が、古典型Fabry病患者、亜型Fabry病患者、健常者のいずれに由来しているかを識別する工程を含む方法。 - 請求項1に記載の方法であって、
当該血液、血清、血漿中、または細胞や組織中において、サポシンC濃度を測定しないことを特徴とする方法。 - 請求項1に記載の方法であって、
当該血液、血清、血漿中、または細胞や組織中において、α−ガラクトシダーゼ活性を測定しないことを特徴とする方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012222578A JP6108384B2 (ja) | 2012-10-04 | 2012-10-04 | α−ガラクトシダーゼ濃度を測定する方法 |
PCT/IB2013/002652 WO2014064528A2 (ja) | 2012-10-04 | 2013-11-27 | α‐ガラクトシダーゼ濃度を測定する方法 |
US14/433,418 US20160069879A1 (en) | 2012-10-04 | 2013-11-27 | Method for measuring alpha-galactosidase concentration |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012222578A JP6108384B2 (ja) | 2012-10-04 | 2012-10-04 | α−ガラクトシダーゼ濃度を測定する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014074667A true JP2014074667A (ja) | 2014-04-24 |
JP6108384B2 JP6108384B2 (ja) | 2017-04-05 |
Family
ID=50545407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012222578A Expired - Fee Related JP6108384B2 (ja) | 2012-10-04 | 2012-10-04 | α−ガラクトシダーゼ濃度を測定する方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20160069879A1 (ja) |
JP (1) | JP6108384B2 (ja) |
WO (1) | WO2014064528A2 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007058381A1 (ja) * | 2005-11-18 | 2007-05-24 | Tokyo Metropolitan Organization For Medical Research | 基質特異性を変換した新規高機能酵素 |
-
2012
- 2012-10-04 JP JP2012222578A patent/JP6108384B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-27 US US14/433,418 patent/US20160069879A1/en not_active Abandoned
- 2013-11-27 WO PCT/IB2013/002652 patent/WO2014064528A2/ja active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007058381A1 (ja) * | 2005-11-18 | 2007-05-24 | Tokyo Metropolitan Organization For Medical Research | 基質特異性を変換した新規高機能酵素 |
Non-Patent Citations (2)
Title |
---|
山田陽子 ほか: "高感度多項目測定技術(MUSTag)を用いたFabry 病の新規診断法の確立", 生化学, vol. 3P-1172, JPN6016030276, 2007, ISSN: 0003375312 * |
芝崎太 ほか: "MUSTag 法による蛋白バイオマーカーの超高感度多項目測定と簡易・迅速診断への応用", 臨床病理, vol. 57巻 11号, JPN6016030277, November 2009 (2009-11-01), pages 1104 - 1112, ISSN: 0003495197 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014064528A2 (ja) | 2014-05-01 |
US20160069879A1 (en) | 2016-03-10 |
WO2014064528A3 (ja) | 2015-01-15 |
JP6108384B2 (ja) | 2017-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210108273A1 (en) | Compositions And Methods For Treating Or Preventing Prostate Cancer And For Detecting Androgen Receptor Variants | |
Wang‐Johanning et al. | Detecting the expression of human endogenous retrovirus E envelope transcripts in human prostate adenocarcinoma | |
US20150177246A1 (en) | Fusion gene of cep55 gene and ret gene | |
JP5346507B2 (ja) | 抗体複合体、抗原検出方法、及び抗体複合体製造方法 | |
WO2015035452A1 (en) | Bimolecular protease-based biosensor | |
US20190203280A1 (en) | Composition and method for improving sensitivity and specificity of detection of nucleic acids using dcas9 protein and grna binding to target nucleic acid sequence | |
US8822163B2 (en) | Method for measuring β-glucan, and β-glucan-binding protein for use in the method | |
KR101698654B1 (ko) | En2에 특이적으로 결합하는 dna 압타머 및 이의 용도 | |
JP4621593B2 (ja) | フォンヴィルブランド因子分解酵素の測定による血栓症の検出方法 | |
TW202219272A (zh) | SARS-CoV-2之偵測 | |
EP1962091B1 (en) | Methods and kits for detecting and measuring ADAMTS13/FX1 complexes | |
JP6108384B2 (ja) | α−ガラクトシダーゼ濃度を測定する方法 | |
JP2020516280A (ja) | 角膜ジストロフィーに関連する対立遺伝子の多重検出のための方法 | |
WO2018128286A1 (ko) | 핵산의 신속 검출법 및 이를 이용한 질병의 신속 진단 방법 | |
US20200407467A1 (en) | Protease activity profiling via programmable phage display of comprehensive proteome-scale peptide libraries | |
US8663912B2 (en) | Fluorogenic substrate for ADAMTS13 | |
WO2002077623A1 (en) | Probe for visualizing phosphorylation/dephosphorylation of protein and method of detecting and quantifying phosphorylation/dephosphorylation of protein | |
US20130109107A1 (en) | Diagnosis and treatment of autoimmune disease | |
CA3108832A1 (en) | Synthetic peptide for detecting hiv-1 | |
JP2007057509A (ja) | ネコアクチビンaの測定方法およびその測定キット | |
KR102684067B1 (ko) | DNA 및 RNA 동시 검출을 위한 Cas 복합체 및 이의 용도 | |
WO2024135797A1 (ja) | ジストロフィンの測定方法 | |
JP2006516888A5 (ja) | ||
JP2011115146A (ja) | 新規ペプチド及びその使用 | |
US8313917B2 (en) | Methods of diagnosing latent and active malignancies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150918 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20151125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161011 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170214 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170301 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6108384 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |